|
Virtual Meetings 2022
Meet The Professor: Optimizing the Management of Ovarian CancerFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Prof Jonathan A Ledermann Professor of Medical Oncology UCL Cancer Institute London, United Kingdom Stephanie Lheureux, MD, PhD Drug Development Program ‑ Gynecology Division of Medical Oncology and Hematology Gynecology Site Lead Co-Director of the Beyond Chemotherapy Program Princess Margaret Cancer Centre Associate Professor University of Toronto Toronto, Ontario, Canada Ursula Matulonis, MD Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, Massachusetts Richard T Penson, MD, MRCP Associate Professor of Medicine Harvard Medical School Clinical Director, Medical Gynecologic Oncology Massachusetts General Hospital Boston, Massachusetts Shannon N Westin, MD, MPH Associate Professor Director, Early Drug Development Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston, Texas SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Mersana Therapeutics Inc. Agenda
MODULE 1: Current Treatment Paradigm for Newly Diagnosed and Recurrent Ovarian Cancer MODULE 2: Optimal Incorporation of PARP Inhibitors into the Treatment Algorithm MODULE 3: Management of Side Effects Associated with PARP Inhibitor Therapy MODULE 4: Novel Investigational Agents and Strategies for Ovarian Cancer
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Prof Ledermann — Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Merck, Merck Sharp & Dohme LLC, Nuvation Bio, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Merck Sharp & Dohme LLC, Neopharm, Tesaro, A GSK Company. Dr Lheureux — Advisory Committee: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline, Merck, Novartis, Novocure Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Regeneron Pharmaceuticals Inc, Repare Therapeutics, Roche Laboratories Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Roche Laboratories Inc. Dr Matulonis — Advisory Committee: 2X Oncology, Agenus Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Clearity Foundation, ImmunoGen Inc, NextCure, Ovarian Cancer Research Alliance, Rivkin Foundation, Trillium Therapeutics Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Novartis; Contracted Research: FUJIFILM Pharmaceuticals USA Inc, ImmunoGen Inc, Merck, Mersana Therapeutics Inc; Data and Safety Monitoring Board/Committee: Advaxis Inc, Alkermes, Symphogen A/S. Dr Penson — Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Royalties: BMJ Publishing Group Ltd, Elsevier, Wiley-Blackwell, Wolters Kluwer Health. Dr Westin — Consulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Bio, Nuvectis Pharma Inc, Seagen Inc, Vincerx Pharma, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bio-Path Holdings, Clovis Oncology,Genentech, a member of the Roche Group, GlaxoSmithKline, Mereo BioPharma, OncXerna Therapeutics Inc, Zentalis Pharmaceuticals.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Mersana Therapeutics Inc. |